drug · protein
patient view →lutetium Lu 177 dotatate
Marketedupdated 2mo agoby Advanced Accelerator Applications SA🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for neuroendocrine neoplasm and neuroendocrine carcinoma and 7 investigational indications.
targets
Somatostatin receptor
all catalysts(0)
nothing on the calendar yet
News(1)
- Novartis' radioligand therapy Lutathera could soon face generic competitionThe radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis. Radioligand therapy aims to bring th…endpoints · 2mo ago
comments(0)
5-min edit window · permanent after that